usdaed

When things get rumblingly unpleasant in places like the Mideast – and let’s face it, they often do – people get the jitters. They start thinking, “Good heavens, what if everything goes horribly wrong?” And when they think that, they rush about buying gold. It’s a perfectly ridiculous habit, of course, but a profitable one for the gold miners. This time, they did just that. But the trouble is, gold gets bored. It doesn’t like being fussed over. So, after a brief excitement, it decides to sulk and the price slithers downwards. And when gold slithers, Newmont wobbles.

Yet, it is precisely in these moments of quietude that opportunity reveals itself. The recent decline in valuation, viewed by some as a cause for alarm, strikes me as a rather…excessive reaction. A harsh judgment upon a company that, despite its present circumspection, possesses a core strength that few can rival. It is a stock, in my estimation, unduly punished, and thus, a most attractive proposition for a patient investor.

The market, as these things will, has responded with a degree of skittishness. Oil, naturally, is taking the brunt of it, currently flirting with the ninety-nine dollar mark – a positively dizzying sum, and a good seventy-two percent higher than where it was earlier in the year. One shudders to think what the cost of petrol will be if this carries on!

He’s worried about the situation in, shall we say, the hotter regions of the world, and rightly so. Wars are rarely kind to ledgers. A brief flurry of activity, a bit of disruption to the oil flow, and suddenly everyone’s paying more for… well, everything. Dimon’s assessment, delivered with the sort of grim practicality that suggests he’s already priced it into his models, is that a short-lived conflict won’t be catastrophic. But he’s also warning us not to be complacent. Complacency, in my experience, is merely a polite word for ‘about to be very, very wrong.’

Nu Holdings, operating primarily through its digital banking platform Nu Bank, has established a significant presence in the Brazilian, Mexican, and Colombian financial landscapes. With a customer base exceeding 131 million, the company appears poised to consolidate its position as a dominant force in Latin American consumer banking.

February closed around $2,078 an ounce. Then, the predictable spike. Up to $2,416 when the US and Israel started… well, doing things. Briefly. Before gravity remembered it exists. Now? Back down to $2,079. A 1.5% drop. Silver’s following suit. Because, naturally, it does. Closed at $93.73, peaked at $96.10. Now it’s at $83.90. A slightly less dramatic fall, but a fall nonetheless. Coeur mines both, so they’re getting a double dose of disappointment. Which, let’s be real, is entirely deserved.

And that’s the problem. We’ve forgotten what a real pullback feels like. The creeping fear, the late-night doomscrolling, the unsolicited investment advice from people who peaked at Beanie Babies. If the economy decides to cooperate with the general sense of unease, we might be in for another one soon. And when that happens, it’s usually not the blue chips leading the charge. It’s the scrappy little companies, the ones nobody notices until they’re suddenly, unexpectedly, thriving.

The projections for the coming year are bold, a declaration of potential riches. Yet, it is not the anticipated blossoming of the American market that fuels this ambition, but a curious diversion – the acquisition of breweries. A strange alchemy, indeed, to seek growth in fermented barley when the very earth offers a more promising yield. One observes this strategy and wonders if the management, like so many men of commerce, has lost sight of the fundamental principles, chasing shadows instead of substance.

Pfizer. They’ve been at the AI game for a while, apparently. Before it was even cool. Back when they were busy saving the world with the Covid vaccine (and, let’s be real, making a rather handsome profit). They used AI for that, you know. Speeding things up. Which is good. Because waiting is so stressful. Now they’re trying to apply it to everything – drug discovery, manufacturing, the works. It’s admirable, really. A bit like watching someone desperately trying to learn a new skill after years of doing things their own way.